Literature DB >> 19403937

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.

M D Galsky, K Simon, G Sonpavde, T E Hutson, M Fleming, G V Kondagunta, W Berry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19403937     DOI： 10.1093/annonc/mdp199

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

Review 2.  Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

Authors:  George Orphanos; Alexandros Ardavanis
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

Review 3.  Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

Authors:  A Oliver Sartor
Journal:  J Hematol Oncol       Date:  2011-04-23       Impact factor: 17.388

4.  Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.

Authors:  E N Lo; L A Beckett; C X Pan; D Robles; J M Suga; J M Sands; P N Lara
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-10       Impact factor: 5.554
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.